Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01178346 · ClinicalTrials.gov registry record · Phase 3
Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies
A Phase 3 study of Smoking Cessation, sponsored by Nabi Biopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT01178346 is a Phase 3 study of Smoking Cessation that has completed, run by Nabi Biopharmaceuticals. The registered enrollment target is 500 participants, roughly in line with the 472-participant average among 188 other Smoking Cessation trials with a reported enrollment target. The trial reports 20 study locations across 13 states.
The verdict
NCT01178346, a Phase 3 study of Smoking Cessation, has completed, sponsored by Nabi Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to look at pharmacoeconomic data for subjects that have received either NicVAX or placebo in the Nabi-4514 or Nabi-4515 studies.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL NicVAX vaccine
Study Locations (20)
California
- NicVAX Investigator - Encino
- NicVAX Investigator - Los Alamitos
- NicVAX - Newport Beach
- NicVAX Investigator - San Diego
Florida
- NicVAX Investigator - Brooksville
- NicVAX Investigator - Orlando
- NicVAX Investigator - St. Petersburg
- NicVAX Investigator - Tampa
Minnesota
- NicVAX Investigator - Minneapolis
- NicVAX Investigator - Rochester
Arizona
- NicVAX Investigator - Tucson
Colorado
- NicVAX Investigator - Denver
Idaho
- NicVAX Investigator - Boise
Indiana
- NicVAX - Indianapolis
Louisiana
- NicVAX Investigator - Metarie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01178346
The ClinicalTrials.gov registry entry for NCT01178346 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 472-participant average among 188 other Smoking Cessation trials with a reported enrollment target. The listed sponsor is Nabi Biopharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoking Cessation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01178346 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01178346 about?
NCT01178346 is a clinical study titled "Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies". The purpose of this study is to look at pharmacoeconomic data for subjects that have received either NicVAX or placebo in the Nabi-4514 or Nabi-4515 studies.
What is the current status of trial NCT01178346?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2010-07. Estimated completion is 2011-11.
What conditions does trial NCT01178346 study?
This clinical trial studies the following conditions: Smoking Cessation.
What interventions are being tested in trial NCT01178346?
The interventions under investigation include: Placebo (BIOLOGICAL), NicVAX vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01178346?
This trial is sponsored by Nabi Biopharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01178346 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tobacco Education and Lung Health Study (TEAL)
RECRUITING · Phase 3
-
V+PSF-M for Tobacco Cessation in HIV Care in India
RECRUITING · Phase 3
-
Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment
RECRUITING · Phase 3
-
Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype
COMPLETED · Phase 3
-
Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).
COMPLETED · Phase 3
-
Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.